Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Pembrolizumab (MK-3475) as First-Line Therapy for High Risk T1 Non-Muscle-Invasive Bladder Cancer

Next Previous
Trial Profile

Phase II Study of Pembrolizumab (MK-3475) as First-Line Therapy for High Risk T1 Non-Muscle-Invasive Bladder Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 27 Jun 2018 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
    • 27 Jun 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
    • 27 Jun 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top